human
The task is to decide the Hallmarks of Cancer (HOC) taxonomy of the article based on its abstract. The input is an abstract text. There are 10 topics you will need to decide whether the article is related to. Topics: sustaining proliferative signaling, evading growth suppressors, resisting cell death, enabling replicative immortality, inducing angiogenesis, activating invasion and metastasis, genomic instability and mutation, tumor promoting inflammation, cellular energetics, avoiding immune destruction. The output should be topics from the above 10 topics, that are related to the input article. Please note one article can be related to multiple topics. Output format: provide a semicolon-separated list of relevant topics.
    ###
    INPUT: OBJECTIVE Hepatocellular carcinoma ( HCC ) is a highly vascularized tumor in which neoangiogenesis contributes to growth and metastasis . We assessed the safety , efficacy , and potential biomarkers of activity of bevacizumab in patients with advanced HCC . METHODS In this phase II trial , eligible patients received bevacizumab , 5 mg/kg or 10 mg/kg every 2 weeks . The disease-control rate at 16 weeks ( 16W-DCR ) was the primary endpoint . Circulating endothelial cells ( CECs ) and plasma cytokines and angiogenic factors ( CAFs ) were measured at baseline and throughout treatment . RESULTS The 16W-DCR was 42% ( 95% confidence interval , 27%-57% ) . Six of the 43 patients who received bevacizumab achieved a partial response ( objective response rate [ ORR ] , 14% ) . Grade 3-4 asthenia , hemorrhage , and aminotransferase elevation occurred in five ( 12% ) , three ( 7% ) , and three ( 7% ) patients , respectively . During treatment , placental growth factor markedly increased , whereas vascular endothelial growth factor ( VEGF)-A dramatically decreased ( p &lt ; .0001 ) ; soluble VEGF receptor-2 ( p &lt ; .0001 ) and CECs ( p = .03 ) transiently increased on day 3 . High and increased CEC counts at day 15 were associated with the ORR ( p = .04 ) and the 16W-DCR ( p = .02 ) , respectively . Lower interleukin ( IL)-8 levels at baseline ( p = .01 ) and throughout treatment ( p â¤ .04 ) were associated with the 16W-DCR . High baseline IL-8 and IL-6 levels predicted shorter progression-free and overall survival times ( p â¤ .04 ) . CONCLUSION Bevacizumab is active and well tolerated in patients with advanced HCC . The clinical value of CECs , IL-6 , and IL-8 warrants further investigation .
    OUTPUT:

agent
inducing angiogenesis
The task is to decide the Hallmarks of Cancer (HOC) taxonomy of the article based on its abstract. The input is an abstract text. There are 10 topics you will need to decide whether the article is related to. Topics: sustaining proliferative signaling, evading growth suppressors, resisting cell death, enabling replicative immortality, inducing angiogenesis, activating invasion and metastasis, genomic instability and mutation, tumor promoting inflammation, cellular energetics, avoiding immune destruction. The output should be topics from the above 10 topics, that are related to the input article. Please note one article can be related to multiple topics. Output format: provide a semicolon-separated list of relevant topics.
    ###
    INPUT: OBJECTIVE Hepatocellular carcinoma ( HCC ) is a highly vascularized tumor in which neoangiogenesis contributes to growth and metastasis . We assessed the safety , efficacy , and potential biomarkers of activity of bevacizumab in patients with advanced HCC . METHODS In this phase II trial , eligible patients received bevacizumab , 5 mg/kg or 10 mg/kg every 2 weeks . The disease-control rate at 16 weeks ( 16W-DCR ) was the primary endpoint . Circulating endothelial cells ( CECs ) and plasma cytokines and angiogenic factors ( CAFs ) were measured at baseline and throughout treatment . RESULTS The 16W-DCR was 42% ( 95% confidence interval , 27%-57% ) . Six of the 43 patients who received bevacizumab achieved a partial response ( objective response rate [ ORR ] , 14% ) . Grade 3-4 asthenia , hemorrhage , and aminotransferase elevation occurred in five ( 12% ) , three ( 7% ) , and three ( 7% ) patients , respectively . During treatment , placental growth factor markedly increased , whereas vascular endothelial growth factor ( VEGF)-A dramatically decreased ( p &lt ; .0001 ) ; soluble VEGF receptor-2 ( p &lt ; .0001 ) and CECs ( p = .03 ) transiently increased on day 3 . High and increased CEC counts at day 15 were associated with the ORR ( p = .04 ) and the 16W-DCR ( p = .02 ) , respectively . Lower interleukin ( IL)-8 levels at baseline ( p = .01 ) and throughout treatment ( p â¤ .04 ) were associated with the 16W-DCR . High baseline IL-8 and IL-6 levels predicted shorter progression-free and overall survival times ( p â¤ .04 ) . CONCLUSION Bevacizumab is active and well tolerated in patients with advanced HCC . The clinical value of CECs , IL-6 , and IL-8 warrants further investigation .
    OUTPUT:
